Onconetix (ONCO) Operating Leases (2023 - 2026)

Onconetix (ONCO) posted quarterly Operating Leases of $18311.0 for Q1 2026, down 24.84% quarter-over-quarter from $24362.0 in Q4 2025.

Onconetix (ONCO) Operating Leases (2023 - 2026) Analysis & Trends

Onconetix (ONCO) has reported Operating Leases for 4 consecutive years, with $18311.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $18311.0; the TTM figure through Mar 2026 stood at $18311.0 (changed N/A YoY), while the FY2025 annual figure was $24362.0, changed N/A from the prior year.
Operating Leases declined to $18311.0 in Q1 2026 per ONCO's latest filing, from $24362.0 in the prior quarter.
Across five years, Operating Leases topped out at $74290.0 in Q4 2023 and bottomed at $18311.0 in Q1 2026.
Historically, Operating Leases has averaged $42771.8 across 4 years, with a median of $39579.5 in 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00

Download Data